Boehringer Ingelheim GmbH

Already riding high with positive early data for its long-acting GLP-1 analog candidate MET-097i, Metsera grabbed attention again on June 9 with Phase I data for its amylin analog MET-233i, which prod

Bayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can

While significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o

As a privately held and family-owned pharma firm, Boehringer Ingelheim has more freedom to dance to its own tune than most of its peers, but it has still been candid about the scale of its aspirations